RAndomized Clinical Trial Of NAfamostat Mesylate, A Potent Transmembrane Protease Serine 2 (TMPRSS2) Inhibitor, in Patients with COVID-19 Pneumonia
Seccia et al., Journal of Clinical Medicine, doi:10.3390/jcm12206618
https://c19early.org/seccianf.html